Friday, August 24, 2012

AstraZeneca - Its time to be optimistic - Great Article On Seekingalpha

AstraZeneca - Its time to be optimistic
AstraZeneca (AZN) is trading at 7.7 times 2012 earnings and at the current price the dividend yield is 6%, which is best in the industry. You may call the valuations attractive or dismal depending on the way you look at it. Investors are pessimistic on AZN's ability to make up for the huge patent expiries that it faces in the next five years (2012-16). The concerns are genuine, but I would prefer to be optimistic now, as I see the worst case scenario priced in.
AZN has a comfortable cash position and is constantly eying strategic maneuvers, (alliances and M&A opportunities) to rejuvenate growth. On June 30, AZN joined hands with Bristol-Myers (BMY) to acquire Amylin for $7billion. The key products......................................
Source - Seekingalpha